Nurix reports updated trial results for BTK degrader in blood cancers

June 11, 2026 7:01 AM

Nurix Therapeutics Inc. (NASDAQ: NRIX) announced updated clinical data from its ongoing Phase 1a/b trial evaluating bexobrutideg, an investigational BTK ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found